PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials
- Citation:
- Annal Oncol vol 29 (suppl_8) Abstr LBA34
- Meeting Instance:
- ESMO 2018
- Year:
- 2018
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- 3111
- Pharmas:
- Exelixis
- Grants:
- U10CA180821, U24CA196171
- Corr. Author:
- Authors:
- T.K. Choueiri A. Flaifel W. Xie D. Braun M. Ficial R. Jennings A. Nassar B. Escudier D.J. George R.J. Motzer M.J. Morris T. Powles E. Wang Y. Huang G. Freeman S. Signoretti
- Networks:
- LAPS-CT018, LAPS-MA036, LAPS-NC010, LAPS-NY016, LAPS-NY158, LAPS-UT003, NC002
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: